Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Gilead Sciences

Gilead Sciences (NASDAQ: GILD) insider transactions

In the twelve months to 10 November 2026, executives and directors of Gilead Sciences reported 86 open-market sales of 776,746 shares ($112.3m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Gilead Sciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 November 2026Cain Wettan Keeley MEVP Gen Counsel, Legal & CompOpen-market sale, 10b5-1 plan−3,399$164.115,360Form 4
5 November 2026O'Day Daniel PatrickChairman & CEOOption exercise, 10b5-1 plan+9,810$72.34561,493Form 4
5 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−9,810$175.17551,683Form 4
4 November 2026O'Day Daniel PatrickChairman & CEOOption exercise, 10b5-1 plan+102,619$72.34654,302Form 4
4 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−102,619$175.16551,683Form 4
2 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−1,600$167.40565,083Form 4
2 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−1,700$168.10563,383Form 4
2 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−1,904$169.27561,479Form 4
2 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−7,796$170.35553,683Form 4
2 November 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−2,000$171.06551,683Form 4
30 October 2026O'Day Daniel PatrickChairman & CEOOption exercise, 10b5-1 plan+15,881$72.34582,564Form 4
30 October 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−15,881$175.25566,683Form 4
15 October 2026Dickinson Andrew DChief Financial OfficerOpen-market sale, 10b5-1 plan−3,000$156.22161,096Form 4
15 October 2026Mercier JohannaChief Comm & Corp Aff OfficerOpen-market sale, 10b5-1 plan−3,000$156.22113,684Form 4
1 October 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−12,000$147.72569,683Form 4
1 October 2026O'Day Daniel PatrickChairman & CEOOpen-market sale, 10b5-1 plan−3,000$148.63566,683Form 4
22 September 2026Burkhart ErinSVP, ControllershipOption exercise+2,223—2,223Form 4
22 September 2026Burkhart ErinSVP, ControllershipShares withheld for tax−768$152.671,455Form 4
15 September 2026Dickinson Andrew DChief Financial OfficerOpen-market sale, 10b5-1 plan−3,000$145.29164,096Form 4
15 September 2026Mercier JohannaChief Comm & Corp Aff OfficerOpen-market sale, 10b5-1 plan−1,600$143.69118,084Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Gilead Sciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.